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ABSTRACT
Parkinson’s disease (PD) is a neurological disorder with complicated and disabling motor
and non-motor symptoms. The pathology for PD is difficult and expensive. Furthermore,
it depends on patient diaries and the neurologist’s subjective assessment of clinical scales.
Objective, accurate, and continuous patient monitoring have become possible with the ad-
vancement in mobile and portable equipment. Consequently, a significant amount of work
has been done to explore new cost-effective and subjective assessment methods or PD
symptoms. For example, smart technologies, such as wearable sensors and optical motion
capturing systems, have been used to analyze the symptoms of a PD patient to assess their
disease progression and even to detect signs in their nascent stage for early diagnosis of
PD.
This review focuses on the use of modern equipment for PD applications that were de-
veloped in the last decade. Four significant fields of research were identified: Assistance to
Diagnosis, Prognosis or Monitoring of Symptoms and their Severity, Predicting Response
to Treatment, and Assistance to Therapy or Rehabilitation. This study reviews the pa-
pers published between January 2008 and December 2018 in the following four databases:
Pubmed Central, Science Direct, IEEE Xplore and MDPI. After removing unrelated ar-
ticles, ones published in languages other than English, duplicate entries and other articles
that did not fulfill the selection criteria, 778 papers were manually investigated and included
in this review. A general overview of PD applications, devices used and aspects monitored
for PD management is provided in this systematic review.
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Chapter 1
INTRODUCTION
Parkinson’s disease (PD) is a complex neurodegenerative disorder that affects the overall
quality of life (QoL) of the patient and their caregivers. Approximately 60,000 individuals
in the United States are diagnosed with PD each year, while more than 10 million people
are living with PD worldwide [45, 83]. PD is accompanied by many significant motor
signs: tremor, rigidity, bradykinesia, hypokinesia, postural instability, gait difficulties and
freezing of gait. While its pathology is usually based on these motor symptoms, many non-
motor symptoms are also manifested with this disease. These non-motor symptoms are
commonly evident and, at times, even more, disabling than the motor symptoms. Common
non-motor signs of the disease are cognitive impairment, reduced ability to smell, dementia,
depression and emotional changes. It is a progressive disorder whose symptoms become
more noticeable with age. Only an estimated 4% of people with PD are diagnosed before
the age of 50 because it is difficult to detect and treat in its nascent stages.
Currently, the pathology of PD is based on the assessment of the motor and non-motor
symptoms during a neurological examination, during which a neurologist watches the pa-
tient perform some specific task. This process of diagnosis and evaluation of disease pro-
gression by visual inspection is sub-optimal as it can be affected by subjectivity of the
clinician. Additionally, the neurologist assigns scores to the tasks performed by the patient
during the examination, as described by the Unified Parkinsons Disease Rating Scale (UP-
DRS) [41] or its updated version, the Movement Disorder Society-sponsored revision of the
UPDRS (MDS-UPDRS) [53]. Another rating scale, the Hoehn and Yahr scale (HY) [61]
assigns an overall score out of 5 to the patient based on their pathological stage. All these
clinical scales are subjective and lead to high inter-rater variability among neurologists and
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clinics, and thus they are not entirely reliable. Early and accurate diagnosis of PD is of vital
importance as it can help in better prognosis and treatment. It can improve the QoL of the
patient, while a misdiagnosis can cause a delay in proper treatment. The treatment plan for
a PD patient should also be personalized and adhere to the individual needs and predomi-
nant symptoms. The clinical assessment of PD also depends on the change in the symptoms
noted in the patient’s diary. The credibility of such reports are limited by subjectivity and
recall bias of the patient [100, 14].
The medication alone can cost $2,500 a year, and corrective surgeries like Deep Brain
Stimulation (DBS) cost up to $100,000 per person [45]. For example, imaging equipment,
such as magnetic resonance imaging (MRI), single-photon emission computed tomography
(SPECT) and positron emission tomography (PET), are used to assist the neurologist in
making an objective and more accurate diagnosis [141]. The high cost of such equipment
factor into the expenses of diagnosis and treatment of Parkinson’s Disease [18]. As a
result, many patients tend to ignore their symptoms during the prodromal stage and do
not go through proper diagnosis. The primary medication for PD is levodopa, which is
highly effective and widely used. However, prolonged usage may lead to complications
like Levodopa-Induced Dyskinesia (LID).
Additionally, routine visits to clinics for assessment of disease progression is not ideal
for the patients and also not sufficient. Freezing of gait (FoG) and falls are significant
causes of injuries for PD patients. Since it is not possible for caregivers to be vigilant and
continuously monitor the movements of the patients, an automated monitoring system can
be useful. Moreover, a remote monitoring platform can assist clinicians with older patients,
have progressing disabilities, and have difficulty making regular trips to the clinic.
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1.1 Modern Technologies in Parkinson’s Assessment
The development of mobile computing technologies has made the long-term objective
measurement of symptoms in PD possible. Popular devices include Inertial Measurement
Units (IMUs), Force and Pressure plates, Biopotential sensors, and Optical Motion Captur-
ing Systems. IMUs usually include sensors like accelerometer and gyroscope which can
record essential data for analyzing the symptoms of a patient. Force sensors in a force plate
can give information about the patient’s posture and balance. Neural activity and muscu-
lar response can be measured using biopotential sensors like Electroencephalogram (EEG)
and Electromyogram (EMG), while Optical Motion Capturing systems like VICON and
Microsoft Kinect can be used for body motion analysis of a patient in their ambulatory
environment. With the growing popularity of Body Area Network (BAN), Wide Area Net-
work (WAN) and communication protocols like Zigbee and Bluetooth, the networking of
these sensors have also become more straightforward. In the last decade, a growing num-
ber of scientists have developed innovative assessment techniques for PD using modern
technologies. Acceleration data collected during a walking task or a Timed up and Gait
examination is recorded for gait quality assessment of a patient. Data collected from IMUs
have also been used for identifying physical activities for continuous monitoring [13]. Fur-
thermore, EMG data recorded from the skin of a patient is used to measure tremor. The
measurement of these symptoms is then used to determine the severity of the symptoms or
to aid in the diagnostic procedure.
1.2 Limitations in Modern Technologies
The use of modern technologies has shown promising results so far. Still, their wide-
spread adoption is limited by many technical and acclimatization challenges [14]. The
International Parkinson and Movement Disorders Society Task Force on Technology listed
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the problems as limited compatibility between sensors used, discrepancy between clin-
ical needs and scientific research, lack of biomarkers for monitoring non-motor symp-
toms, relevance of data collected by sensors, lack of efficient algorithms for analyzing
sensor data and practical limitations in patients using the technologies for continuous mon-
itoring under a tight energy budget [40, 12]. Majority of the systems developed with
modern technologies focus on the motor symptoms of PD, such as, tremor, bradykine-
sia, gait abnormalities, dyskinesia [40, 117, 141, 104, 36, 35, 118]. Few studies focused
on the non-motor symptoms of the disease, such as depression, dementia, cognitive im-
pairment [29, 79, 37, 19, 133]. The measurement of non-motor symptoms is still based on
clinical measurements, like blood pressure, and MRI scan. Thus there is an urgent need of
developing cost-effective, unobtrusive measurement techniques for non-motor symptoms
for remote monitoring of patients.
The lack of a large sample size for testing of solution limits their credibility and gen-
eralizability. For a solution to be accepted clinically, it should be tested on a large number
of PD patients to ensure that it is not specific to a particular category of symptoms or
personalized for a small set of subjects. Finally, the bridge between the clinical needs
and scientific research can limit the development of specific technology-based objective
measurements (TOMs) [40, 14]. A cohort between the clinical and technical community to
develop symptoms-specific TOMs and identify the efficient analysis techniques is required.
Figure 1.1(a) illustrates the current assessment of PD symptoms. The health professionals
assess the patients during periodic clinic visits, and the technology professionals develop
measurement devices for PD assessment. But there is none or little information exchange
between the three groups. A better approach is illustrated in Figure 1.1(b) where the tech-
nology professionals consult the clinicians to know what is required to be measured and
to identify the TOMs. The patients or users give feedback about their experience. These
inputs help technology professionals develop a personalized device for objective measure-
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ment of PD symptoms. The user and the clinicians also get regular feedback from the
device which enables continuous monitoring of symptoms.
Advances in wearable computing system enable a wide range of monitoring, diagno-
sis, and therapy applications [78, 95, 101]. For example, wearable devices can be used
for human activity recognition [72, 13], assistive technologies [94, 93, 138], and decoding
human intent [120, 49], The ability to record data from specific sensors is not sufficient
unless there is a proper algorithm to analyze the data set and reveal disease-specific infor-
mation. Clinical expertise is needed to identify reliable features, while technical knowledge
is required to develop and use advanced data analysis techniques. Furthermore, adaptation
challenges require the technology developers to consider user comfort, in technical re-
quirements [100]. A universal monitoring system should be flexible, inconspicuous, easy
to use and easy to manage [14]. Recently proposed wearable devices based on flexible hy-
brid electronics address these problems by presenting physically wearable devices [15, 55].
Another adaptation challenge is repeated charging requirements, which can be difficult for
the user and cause distress [100]. Therefore, there is also a strong need for multi-modal
energy harvesting and optimum energy management techniques to improve the usability of
wearable devices by eliminating battery charging requirements [16, 103].
1.3 Key Contributions
This thesis presents a systematic review of articles published between January 1, 2008,
and December 31, 2018. An electronic database search in Pubmed Central, Science Direct,
IEEE Xplore, MDPI was done to retrieve the relevant articles. After the automatic filtering
using the keywords, these articles are inspected and classified manually. We identified
the following aspects of these papers: (1) The application areas of the proposed solution,
(2) the symptoms measured for the application, (3) the devices used for measuring the
symptoms, and (4) the sensors included in the devices. The papers under study and our
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Figure 1.1: (a) Current practice of healthcare for Parkinson’s Disease assessment (b) Requirement
for objective assessment of Parkinson’s Disease
classification are saved in a spreadsheet and released to the public at https://bit.
ly/2HVwKZ0. The spreadsheet can be updated as new solutions are developed in the
future. Hence, it can serve as a platform for technology professionals and clinicians to
find innovative developments in the area. Furthermore, this spreadsheet can be used by
researchers working in this area to compare their work with the other existing work in
their field. The manually labeled data from this spreadsheet can also enable automatic
classification of papers studying PD symptoms with modern devices.
We have also developed an automated filtering framework for articles focusing on PD
assessment with novel technologies based on their content in Title, Abstract, and Keywords
(TAK). The filtering criteria are made following the PRISMA standards, and they follow
the PICO strategy [74]. Manual filtering is limited by time and subjectivity, which can be
avoided by our filtering framework. It can objectively select the relevant articles for any
systematic review or for finding the related literature in a specific field of work. It can also
detect duplicate items across multiple databases and filter them out. The automated script
makes the review easily reproducible for publications published in the future.
We also use the categorized articles to:
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• Analyze the trends in the use of technology for PD research. For example, we use
the data to identify the most popular application areas and the areas that receive
increasing attention.
• Analyze the devices used in each application area, and how the use of devices has
progressed in the last decade.
• Analyze the symptoms measured to develop solutions in each application area and
determine the most useful devices for measuring the different traits.
• Examine the overall trend of research in this field and how it is going to progress in
the coming years.
1.4 Thesis Organization
The rest of this thesis is organized as follows. In Chapter 2, we discuss the related
research which has worked on a systematic review of different articles focusing on new as-
sessment techniques of Parkinson’s Disease or its symptoms and analyzed them. In Chap-
ter 3, we start by introducing the search and filtering methodology, then we show that it is
performed following the PRISMA guidelines and PICO strategy. Then, we elaborate the
classification methodology, where we describe each of the four application areas, the de-
vice categories and the symptom areas measured. We also explain the criteria for inclusion
in these categories. After this, we explain the analyzing strategies. Chapter 3 also presents
the percentage of articles in each application area and the number of articles using each
device and symptoms. Chapter 4 describes the results of the classification and the analysis
of the results. We analyzed the articles in each application areas and highlighted some of
the most notable works in these areas. The classification snapshots of these articles are
elaborated in Tables 4.1 - 4.4. We also analyze the different devices used and the notable
works related to the devices. The device usage trend and the most commonly used devices
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for each application area are also discussed.
Additionally, we discuss the symptoms measured and the devices used for their mea-
surements. We also observe the traits that have not been sufficiently given focus in the last
decade. Finally, Chapter 5 presents the outcome as well as the direction for future work.
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Chapter 2
RELATED WORK
A large number of studies have been conducted in recent years that investigated the use of
wearable sensors and other technologies to assess the symptoms of a patient suffering from
neurological disorders [40]. There is also a growing interest in getting an unbiased analysis
of the efficacy of technology-based devices that can be used in scientific research of health
monitoring and clinical practices [52]. For example, Godinho et al. reviewed 168 articles
after searching the PubMed database and grouped the studies based on the type of device
used [52]. They classified the devices as (i) ‘recommended’, (ii) ‘suggested’ or (iii) ‘listed’
based on the following criteria: (1) used in the assessment of Parkinson’s disease, (2) used
in published studies by people other than the developers, and (3) successful clinimetric
testing. They concluded that objective sensing technology is gaining a lot of attention in
the study of Parkinson’s Disease, but the clinimetric properties and testing of the devices
remain a controversy. They surmised that PD symptoms like postural control, bradykinesia,
tremor, freezing, dyskinesia, gait, and daily activity/physical activity could be objectively
measured using the reviewed devices.
With the increased use of smart technologies, their application in the assessment of PD
symptoms has also increased in recent years [117]. With the advancement in wearable tech-
nologies, early diagnosis, differential diagnosis and objective quantification of symptoms
over time have become much easier for clinicians. Wearable sensors have shown promise
in PD diagnosis and management, as well as for other pathology [59, 116, 23, 35]. For
example, Daneault discussed how wearable and mobile technologies could improve the
management of Essential Tremor (ET) [35]. ET is one of the most common movement
disorders, and millions of people are affected by it worldwide. Due to several barriers, a
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method to clinically manage its symptoms still does not exist. The study proposed 7 differ-
ent areas in which mobile and wearable technology can improve the clinical management
of ET and review the current state of research in these areas. The author concluded that the
presence of mobile and wearable technology everywhere could be leveraged to improve the
quality of life of the patients if clinicians, engineers, and computer scientists work together
on addressing the current knowledge gaps.
The International Parkinson and Movement Disorders Society Task Force on Technol-
ogy had summarized their deliberations about the growing influence of technology in the
diagnosis and monitoring of PD patients in the last 10 years [40]. Espay et al. specifically
looked into the Task Force finding on the challenges and opportunities in the develop-
ment of technologies with the potential for improving the clinical management and QoL
of patients with PD. The Task Force stated the importance of identifying technology-based
objective measures (TOMs) to improve the sensitivity, accuracy, reproducibility, and fea-
sibility of objectively capturing the full complexity and diversity of changes in motor and
non-motor behavior. After reviewing the different advances in using wearable and other
new technologies for PD assessment, 6 challenges were identified: (1) the need for mon-
itoring non-motor symptoms, (2) limitations of sensors used to control motor symptoms,
(3) discrepancy between clinical needs and research, (4) lack of compatibility among wear-
able systems, (5) limitations of available analytical methods, and (6) practical limitations
in user engagement. The review also identified the new opportunities that wearable sys-
tems provide: (1) standard measurement platform, (2) multi-domain measurements, (3)
better phenotyping and subtyping, (4) precision medicine, (5) closed-loop (feedback) sys-
tems, (6) real-time symptom tracking, (7) the promise of remote monitoring, and (8) better
monitoring, better patient engagement, better outcomes. They concluded that, despite all
the challenges, the new and upcoming technologies had enabled the collection of disease-
relevant data. They further stated that to be able to leverage this opportunity into enhanced
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care, better self-management options for PD patients and overall improved healthcare out-
comes, technologies need to be: (1) developed as open platforms and integrated with elec-
tronic medical record systems, (2) suitable for the acquisition of data that captures motor
and non-motor phenomena, and (3) incorporated in treatment delivery systems.
Vienne et al. provided a thorough assessment of features of IMUs and their clinimet-
ric characteristics [137]. In their systematic review, they compared the InertiaLocoGraphy
(ILG) protocols, analyzed the features extracted from inertial signals and proposed a semi-
ological analysis of the quality of the measurements. They searched PubMed, Chochrane
and EMBASE for articles assessing gait quality by IMUs, published between January 1,
2004, to August 31, 2016. A total number of 78 full-text articles were selected, and the fol-
lowing pathological conditions about the studies were identified from them: (1) Environ-
ment: laboratory vs. ambulatory, (2) Floor type and sequence of steps, (3) Walking speed,
(4) Sensitization tactics, (5) Aid. Furthermore, they inspected the studies to determine the
choice and position of the sensor. In a different study by Rodgers et al., recent advances in
wearable sensors and systems that monitor movement, physiology, and environment were
discussed [116]. The articles presented in this review were studies focused on applications
for PD, stroke, and head and neck injuries. This review examined the advances in “non-
invasive sensor” that monitors activities, the environment, and physiologic functions. They
analyzed a collection of recent technology advances and applications that show the poten-
tial of these technologies to improve the Quality of Life of the patients. Three primary
medical use-cases for wearable sensors are described: (1) Parkinson’s Disease, (2) Stroke
Management, and (3) Head and Neck Injuries. Selected research articles in each of these
use cases were discussed. They concluded that recent advances in flexible electronics show
great promise for healthcare monitoring. They further stated the importance of develop-
ing non-invasive techniques for assessing non-motor symptoms like mental state, attention
span and other physiological metrics with high accuracy.
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In recent years, a significant amount of research effort has concentrated on analyzing
gait quality using wearable sensors. However, there is still little consensus among the
research community regarding the efficacy of these studies in detecting gait disturbances
like Freezing of Gait (FoG) and falls. De Lima et al. presented an overview of the use of
wearable devices to detect FoG and falls in PD and assess their performance [36]. They
conducted a systematic search in the PubMed and Web of Science databases using a group
of concept keywords. A total of 27 articles were selected, of which 23 were related to FoG
and 4 to falls. Data extraction was performed using a predefined table. Extracted variables
included: author, sample size, device usage(the type of sensor, number of sensor and sensor
location), data collection procedure, and validation results. Validation was defined by the
ability of the system to measure a concept that it is supposed to measure. Despite promising
validations, the small size of the study samples, the fact that most participants were at the
early stage of the disease and that most of the studies were laboratory-based ensured that
there was still little consensus of algorithm analysis. They concluded that further work was
required in ecological validation and that there was a lack of consistency in the validity
measures and the results reported.
Disease management and development of new treatment strategies primarily depend
on the clinical information derived from rating scales (i.e., UPDRS, H&Y) and patients’
diaries. These sources have various limitations concerning validity, inter-rater variability,
and continuous monitoring [141]. Low compliance and recall bias [100] also limits the
usefulness of patient diaries. Thus, an objective long-term measurement of the motor func-
tions in PD patients is necessary. In a review made by Yang et al., they discussed the recent
developments in sensor technology and how those can be possible replacements of the cur-
rent rating scales [141]. They introduced the objective measurements of motor functions
in PD based on the wearable sensors from the perspective of three primary applications:
Diagnosis/Early Diagnosis, Home-based monitoring and Severity evaluation/progression
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monitoring. This motivated us to create classification criteria based on PD-focused appli-
cations. Rovini et al. [117] conducted a systematic review focused on wearable devices for
PD applications and identified 5 main fields of work: early diagnosis, tremor, body mo-
tion analysis, motor fluctuations, and home and long-term monitoring. The research was
conducted using 3 databases: IEEE Xplore, Science Direct and PubMed Central, between
January 2006 and December 2016. After applying the selection strategy and exclusion cri-
teria, 136 papers were thoroughly evaluated and included in the review, giving an extensive
overview of wearable devices for the management of the different areas of focus in PD
management.
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Chapter 3
METHODOLOGY
In this chapter, we first present our search methodology for articles from PubMed Cen-
tral, Science Direct, IEEE Xplore, and MDPI databases. Then, we elaborate on our se-
lection strategy and the exclusion criteria. Subsequently, we explain our procedure for
creating the Systematic Spreadsheet and how it can be used to assess PD research trends
and influence of various technologies.
3.1 Search Methodology
An electronic database search of articles published between January 1, 2008, and De-
cember 31, 2018, was performed in the PubMed Central, Science Direct, IEEE Xplore and
MDPI databases. These were chosen to allow both medical and engineering journals to be
included in the search process [36]. The systematic search was performed by following
the PRISMA guidelines [74]. The search query included just the keyword ”Parkinson” to
keep the search broad. The title/abstract/keyword and year filters were used to provide
more specificity. The search queries and the number of hits in each database are shown in
Table 3.1.
Only original articles published in English between January 2008 and December 2018,
related to Parkinson’s Disease are included in this systematic review. A total of 28,140
articles were selected to begin with, of which 11,318 were from PubMed Central, 14,540
were from Science Direct, 1709 were from IEEE Xplore, and 573 articles were from MDPI.
After removing articles that were not written in English or were review articles themselves,
22,698 articles were left. The Title, Authors, Publication Title, Year of Publication (YOP),
Keywords, Abstract, Keyword, and DOI were accumulated for all of the 22,698 entries.
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The methodologies used for downloading the data from the four online databases are
also different. The documents were exported in comma-separated values (CSV) format
from IEEE Xplore, tab-delimited format from MDPI and BibTex format from Science
Direct. While, for PubMed Central, we used a Python-based API, Metapub [91] for an
automated search. The information extracted from all of the databases were accumulated
and stored together in a .CSV file.
3.2 Filtering Methodology
Information collected from the aforementioned four databases are used as input for
an automated filtering script written in Python. Based on the PICO strategy [74], the
script uses 4 keyword blocks to implement the selection strategies and the exclusion cri-
teria. The first keyword block had 10 keywords related to the disease (i.e., “Parkinson”,
“Parkinson’s Disease”, “Bradykinesia”, “Dyskinesia”, “Levodopa”, “Freezing of Gait”).
The second block was made of 7 keywords to exclude non-human studies from the study
(i.e., “Rats”, “Primates”, “Marmoset”, “Monkeys”, “Mice”, “Mouse”, “Animal”). The
third keyword block had 66 technology terms related to Parkinson’s Disease assessment
(i.e., “Acceleration”, “Accelerometer”, “Gyroscope”, “Magnetometer”, “Gyro”, “Acc”,
“Exoskeleton device”, “Inertial sensor”, “Video recording”, “Video camera”, “Camera”,
Table 3.1: Search queries used for each database
Database Query Years Hits
Pubmed Central
parkinson[Body - Key Terms] OR parkinson[Abstract]
OR parkinson[Title]
2008 - 2018 11318
Science Direct “parkinson” in Abstract OR Keyword OR Title 2008 - 2018 14540
IEEE Xplore “parkinson” in Abstract OR Keyword OR Title 2008 - 2018 1709
MDPI “parkinson” in Abstract OR Keyword OR Title 2008 - 2018 573
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“EHealth”, “Technology”, “Remote monitoring”, “Home monitoring”, “Telemedicine”,
“Mobile phone”, “Mobile application”, “Precision medicine”, “Digital health”, “Inertial
Measurement Unit”, “IMU”, “Wearable”, “Magneto inertial sensor”, “Sensor”, “Force
plate”, “Force sensor”, “Pressure sensor”, “Gait mat”, “Smartphone”, “Augmented real-
ity”, “Kinect”, “VICON”, “ECG”, “EEG”, “EMG”, “EOG”, “MEG”, “Electrocardiog-
raphy”, “Electroencephalography”, “Electromyography”, “Electrooculography”, “Mag-
netoencephalography”, “Machine learning”, “Classification”, “Auditory cue”, “Auditory
cueing”, “Visual cue”, “Ha[tic cue”, “Vibration”, “Gait classification”, “Insole sen-
sors”, “Leap motion”, “Computer vision”, “Supervised learning”, “Neural networks”,
“Speech disorder”, “Music therapy”, “Smart application”, “Smartphone application”,
“Smart watch”, “Smart pen”, “Touchscreen”, “Digitized tablet”, “Fitness band”, “Op-
tical motion capturing system”). The last keyword block had 11 technology terms related
to Parkinson’s Disease treatment, which we have excluded from our review (i.e., “Positron
emission tomography, “Single-photon emission computed tomography, “Magnetic Reso-
nance Imaging, “Deep Brain Stimulation, “Transcranial, “Neuroimaging, “Brain imag-
ing, “fmri, “SPECT, “PET, “MRI). The keyword blocks were used based on an earlier
review [122].
We developed a script in Python to automate the proposed process. The script goes
through each article’s Title, Abstract, and Keywords (TAK) and compares them with the 4
keyword blocks to objectively determine if the material is relevant to our review or can be
excluded, as shown in Figure 3.1. The first keyword block is applied in the very beginning,
and if it is determined from the TAK that the article is not related to PD, further evaluations
skipped. The second keyword block is then applied to exclude items if the study conducted
was on non-human subjects like rats or monkeys. This keyword block also determines
the clinical feasibility of the studies. The fourth keyword block is then applied to exclude
established diagnostic equipment like Magnetic Resonance Imaging (MRI), Single-photon
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emission computed tomography (SPECT), Positron emission tomography (PET) and treat-
ment methodologies like Deep Brain Stimulation (DBS). Excluding this equipment and
procedures ensures that the studies reviewed are novel approaches for PD assessment. Fi-
nally, the third keyword block is applied to implement the selection strategy. The TAK is
compared with the keywords from this keyword block to determine if the article is using
any technological approach for solving some problem in Parkinson’s Disease.
Our automated filtering process excluded 20,775 articles from the complete list. The
second keyword block excluded 831 articles as they involved studies with technologies
which are out of the scope of this review. 4170 articles were found to be dealing with non-
human subjects by the third keyword block. 15,774 articles were found to be unrelated to
the topics of this review. 1923 articles were selected by the script to be fit for our study. We
then removed the duplicate entries from the set of selected articles and finally are left with
1830 articles. The filtering keywords applied by the automated script accidentally includes
unrelated articles. For example, articles with the terms like “sensor” or “acceleration” are
Figure 3.1: Keyword blocks constructed according to PICOS strategy to determine relevance of a
paper to this review
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included by the script even if they are unrelated; also articles that used “ECG” to mon-
itor “Wolff-Parkinson-White (WPW) syndrome” gets accidentally included by the script.
Such articles are excluded manually during the classification of documents. After manual
inspection 778 articles were identified as relevant and were classified (Figure 3.2).
Figure 3.2: Flow diagram of the systematic review process to new technologies used in assessment
of Parkinson’s Disease in the last ten years
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The articles are saved in a spreadsheet and manually classified using a fixed set of
guidelines as described in Section 3.3. The full flow starting from searching the databases
to the ultimate collection of articles left for manual analysis is illustrated in Figure 3.2.
The Python code used for filtering and removing the duplicate articles will be made
available to the public to offer future studies the opportunity to augment on our review and
include more articles to our database.
3.3 Classification Methodology
The 778 articles were analyzed manually to identify the application areas, the devices
used and the symptoms monitored as shown in Figure 3.2. The details of all the evalu-
ated papers are listed in the publicly shared table made available at https://bit.ly/
2HVwKZ0.
3.3.1 Application Areas
We identified four major application area: Diagnosis/Early Diagnosis, Prognosis/Mon-
itoring the severity of Symptoms, Predicting the response to Treatment, and Therapy in
general. These were identified based on the earlier reviews [141, 117]. The inclusion crite-
ria for an article to be categorized in either of these classes are as follows:
Diagnosis/Early Diagnosis: To date, the diagnosis of Parkinson’s Disease relies on clin-
ical assessment of the motor and non-motor symptoms together, primarily during clinical
assessment by neurologists [68]. The neurologist observes the patient perform specific
tasks and assigns scores as defined in the Unified Parkinsons Disease Rating Scale (UP-
DRS) [41] or its updated version, the Movement Disorder Society-sponsored revision of
the UPDRS (MDS-UPDRS) [53]. Another popular rating scale is the Hoehn & Yahr scale,
which assigns a rating from 1 to 5 to the patient as an overall score of his/her pathologi-
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cal progress [61]. The clinical information derived from these rating scales are subjective
and leads to inter-rater variability and also intra-rate variability [117, 141]. Currently, the
equipment mostly used to supplement the clinicians’ assessment is expensive imaging tools
like SPECT, PET or MRI. Since the correct diagnosis of PD is essential for prognosis and
treatment, objective and cost-effective alternatives to the current tools and techniques are
required. Many researchers have been able to use wearable sensors and other devices to
differentiate PD patients and healthy controls in lab experiments. Additionally, a significant
number of researchers have invested their time in coming up with objective measurements
with cost-effective ways to detect early PD patients with minimal motor abnormalities. If
an article deals with one of the following problems, we classify it in this category:
• Early Diagnosis of patients with Parkinson’s Disease
• Detecting Parkinsonian symptoms in people with untreated PD
• Differentiate patients with Parkinson’s Disease from healthy controls or patients with
a different neurological disorder
• Differentiate PD-related symptoms from similar symptoms but not caused by PD.
For example, differentiating PD tremors from Essential Tremors (ET)
Prognosis/Monitoring the Severity of Symptoms: Currently, the assessment of patient
condition and evaluation of PD severity depends primarily on the clinicians’ judgment and
the patient feedback from diaries and memory. This technique is sub-optimal since it is
neither reliable nor objective. The clinicians’ judgment is subjective [117, 141] while the
patients diary and memory are limited by compliance and recall bias [127, 102, 100]. Thus,
objective remote-monitoring of PD symptoms is required to assess disease progression,
evaluate the severity of the symptoms and continuously monitor the PD patients in unsu-
pervised environments. If an article deals with one of the following problems, we classify
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it as “Diagnosis”:
• Home-based or Remote monitoring of patients with Parkinson’s Disease
• Unsupervised Assisted Living for patients with Parkinson’s Disease
• Evaluating the progression of Parkinson’s Disease in a patient
• Evaluating the severity of PD symptoms in a patient
Predicting Response to Treatment: To measure the efficacy of the treatment or the im-
pact of the medication, clinicians rely mostly on the patients’ complaints and their diaries.
These complaints are subjective and unreliable, and they limit the clinicians’ ability to
make an effective prognosis to build a future treatment plan. This problem has influenced
a lot of research on measuring the impact of a treatment or medication in suppressing the
PD symptoms and also to assess their side effects. We look for the following properties in
an article to see if it falls in this category:
• Measure the effect of treatment like Deep Brain Stimulation in suppressing the pa-
tient’s symptoms over time
• Measure the impact of a medication on the symptoms of the patient
• Measure the side effects of the medicine. For example, levodopa induces dyskinesia
Therapy/Rehabilitation Physiotherapy and other rehabilitation techniques are among
the most common treatments for motion disorders like Parkinson’s Disease. Like medica-
tion, it is crucial to assess their efficacy. Additionally, it has been observed that cues and
feedback are beneficial in assisting a PD patient. A system can provide rhythmic auditory
cues, visual cues or haptic cues to facilitate the movement of a patient. Such a system can
be used for gait training or to assess limb movements. Vibration-based actuators and audio
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feedback are useful to sensitize a patient suffering from Rigidity, Freezing of Gait (FoG),
Tremor or other symptoms of PD and help them to break out of the freeze or can even
suppress the symptom. Studies that use techniques to assist rehabilitation of a patient are
included in this category:
• Audio, Visual or Haptic cue for gait or movement training
• Sensory feedback to suppress a symptom like FoG or Tremor
Figure 3.3: Number of publications between 2008-2018 focusing on each application area.
Figure 3.3 shows that the majority of publications have focused on dealing with prob-
lems related to Diagnosis and Monitoring of PD patients (i.e., 287 and 278 respectively).
A significant share (142) of research papers in this study has also focused on Therapy/Re-
habilitation. Using new technologies to predict the impact of medication in PD patients has
not been given enough attention yet, as only 71 of the articles in this review focus on this
area.
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3.3.2 Domain of Research
Symptoms which are used to assess the progression of a PD patient are referred to
as cardinal PD features. The cardinal PD features are divided into motor symptoms and
non-motor symptoms, as shown in Table 3.2. The motor symptoms are the movement
impairments caused due to Parkinson’s Disease. These symptoms include cognitive im-
pairment, sleep disturbance, fatigue which do not affect the patient’s movement, and these
are the non-motor symptoms of PD. Parkinson’s Disease also causes impairment of speech,
voice and swallowing; such traits are a combination of both motor and non-motor disabili-
ties. Figure 3.4 shows the number of papers that measure the different motor and on-motor
symptoms from the documents we have included in this review. Gait abnormalities are
the most common symptoms measured, followed by tremor and FoG. Movement disorders
like bradykinesia and dyskinesia are also common symptoms in PD patients, and many
research articles use modern measurement techniques to monitor these symptoms. The
neural response is the most commonly measured non-motor trait for PD assessment.
Figure 3.4: Number of publications between 2008-2018 that measure each symptoms.
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Table 3.2: Different domains of assessment of Parkinson’s Disease using new technologies
Symptoms
Motor Symptoms Non-motor Symptoms Mixed Symptoms
Sleep topics
Gait Nerve/Brain signals
Motor activity Cognitive activity
Muscle activity Depression
FoG Dementia
Tremor Heart rate Speech topics
Physical activities Emotions Swallowing
Movement disorders Fatigue
Posture Facial Expression
Balance Blinking
Nocturnal Hypokinesia Facial expression
Handwriting Breath
Saccades Cortical activity
3.3.3 Overview of the Devices for the Assessment of PD
After analyzing the articles related to applications in Parkinson’s Disease, we found
that 8 primary types of devices are used as sensors or actuators on PD patients. The devices
that form each of the categories and their properties are as follows:
Wearable: Wearable sensors have made recording the symptoms of a PD patient much
more comfortable, and many researchers have used wearable sensors in the assessment of a
patient. The devices contain sensors such as accelerometer, gyroscope, magnetometer, etc.
and when placed in specific parts of the patient’s body, parameters such as body movement,
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gait speed, stride length, tremor, etc. can be monitored. The following devices are classified
as wearables in our study:
1. Inertial Measurement Units using sensors like accelerometer, gyroscope, magne-
tometer
2. Insole sensors containing force or pressure sensors that can measure the Ground Re-
action Force (GRF)
3. Wearable devices that can measure muscle activities or neural responses using EEG,
EMG, etc
4. Sensors incorporated with clothes or gloves
5. Other wearable devices like smart glasses or smart caps which can record specific
parameters
Biopotential Devices: Devices that can measure the electrical signal (Biopotentials) that
are generated by the physiological processes in our body. The tools that fall under this
category are Electroencephalogram, Electrocardiogram, Electrocardiogram, Magnetoen-
cephalogram, Electrooculogram, etc.
Cueing Devices: Devices that are used to give feedback or cues to the patients to rectify
their walk or to assist with their movement. Headphones or speakers can be used to deliver
auditory cues, and visual cues can be provided using a screen or a smart glass or even in
a virtual reality environment. Vibration sensors or electrical stimulators have been utilized
to give sensory feedback to patients.
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Optical Motion Tracker: High-end motion capturing systems, such as Microsoft Kinect
and Vicon 3D, are used for motion analysis. A system of multiple IMUs, even camera-
based 3D setups are used to capture the movement of a patient.
Audio Recording: Voice and Speech recording devices, such as microphones and smart-
phones, are used to record the speech tasks or the patient’s voice to analyze the speech of
the patient.
Video Recording: Patients’ movements at home or during laboratory experiments are
often recorded using a video camera to spot symptoms or to corroborate with predictions
from other devices. Usually, a single video-camera is used to record the patient.
Force/Pressure: During laboratory experiment for gait quality assessment or for analyz-
ing the patients’ posture force plates, pressure plates and gait mats that have pressure or
force sensors are used.
Smartphone: More researchers are trying to use the sensors present on-board a smart-
phone (accelerometer, gyroscope, magnetometer, GPS) for different analyses. Smartphone
applications are also used to record the patients’ mood, emotions and even to record the
dosage or medicines. Additionally, the screen of the smartphone can be used to record
handwriting, the microphone to record speech samples, and the camera to record patient
movements.
Other: There are additional devices apart from the ones already mentioned which have
also been used to assess a PD patient. For example, for handwriting assessment, digitized
tablets are used as a smart screen to write on during spiralography exams, and smart pens
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are used to record hand movement during writing. Virtual Reality and Augmented Reality-
based solutions have also started becoming popular in PD applications.
Figure 3.5: Number of publications using new technologies between the years 2008-2018
Figure 3.5 shows that wearable devices are the most commonly used among the papers
included in this systematic review. More than 400 articles in this review use some form of
a wearable device and close to 200 use a biopotential device. Devices that have features
related to more than one categories are included in multiple categories, for example, a
wearable device with a biopotential sensor is included in both groups.
3.4 Data Analysis
Following the classification of the articles using the spreadsheet, the trend of research
over the last 10 years is analyzed. We find the pattern of the research in this domain
according to the application area, the devices used and the field over time. Further study
is done to analyze the reason behind the exponential growth in the number of publications
and to see if there is any correlation with the use of more mobile technologies.
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Chapter 4
RESULTS & ANALYSIS
We observed that of the 778 papers evaluated, 288 (37%) studies focused on diagnosis
or assisting in the diagnosis of Parkinson’s Disease and 280 (36%) papers are focused on
monitoring of patients or prognosis of the disease and the severity of symptoms. Further-
more, 139 (18%) studies were about improving the rehabilitation process of the patients
and improving their quality of life, and 70 (9%) studies analyzed the effect of the medica-
tion and treatment on the symptoms of the patient as shown in Figure 4.1. A majority of
the papers (52%) were published in the last three years (between 2016 - 2018), and 21%
papers in just 2018. Figure 4.2 shows the growing interest in finding alternative objective
ways of assessing Parkinson’s Disease, particularly in the last 3 years.
Figure 4.1: Percentage of publications between 2008-2018 by application area
In this section, we analyze the application areas, the symptoms measured in the target
studies, and the most commonly used devices. Figure 4.2 shows the of the papers included
in our research, the number of articles published every year in the last decade. The total
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number of papers published every year has increased at a constant rate. While between the
years 2016 and 2018 the growth in the number of articles has been at a higher rate.
Figure 4.2: Number of publications using new technologies between 2008-2018
4.1 Application Areas
1. Predicting Response to Treatment: Of the papers included in this review, only 9%
of articles measured the efficacy of the PD treatment in a patient. Levodopa medication is
the most popular treatment for motor and non-motor symptoms of Parkinson’s Disease. It
helps to alleviate bradykinesia, rigidity, tremors and cognitive dysfunction in people with
PD. Still, it is not very clear how such medication improves cognitive or motor opera-
tions in patients with Parkinson’s Disease. George et al. [48] proposed the theory that
dopaminergic drugs improve neural communication by reducing the pathological synchro-
nization within and between the cortex and basal ganglia. They tested their hypothesis by
taking scalp EEG of 16 PD patients when ON and OFF medication, once during a resting
state and again while performing a stop-signal task. Based on their results, they concluded
that dopaminergic medication does improve neural communication during resting state and
while performing executive and motor function.
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In another study by Herz et al. [60], they analyzed the effect of low and high levels
of dopamine on the oscillatory coupling between prefrontal and premotor areas during an
externally paced motor task. They recruited 11 patients with PD and 13 healthy controls
to perform repetitive extension-flexion movements of their right index finger. EEG data of
the participants were recorded while they performed the task. Additionally, the activity in
the right first dorsal interosseus (FDI) muscle of the participants was recorded with sur-
face electromyography (EMG). Their results concluded that dopamine deficiency inhibits
the ability to establish oscillatory coupling between prefrontal and premotor areas during
an externally paced motor task. The effect of levodopa medication in advanced PD was
measured using a wireless wearable EMG device by recording signals from biceps brachii
and kinematic signals from forearm [119]. In another study, instead of using biopoten-
tial sensors, Rigas et al. [111] used a set of wearable sensors to assess PD symptoms and
their severity. Based on the analysis of the outputs of the symptoms detection module, the
system proposes treatment plans for the patient. Pelicioni et al. used an accelerometer
attached to the participant’s head using a light plastic helmet liner and another attached
mid-back at the level of the sacrum to assess gait stability. The participant’s head and trunk
stability during gait were examined during, before and after levodopa intake and between
individuals who took less than or more than 750mg of levodopa medication each day. The
experiment concluded that levodopa intake improved gait stability but only in patients with
no postural instability and gait difficulty (PIGD). In patients with PD PIGD, impaired gait
stability was not only present but was often worsened by levodopa [105].
Another conventional treatment is Deep Brain Stimulation (DBS) of the subthalamic
nucleus (STN). It helps in alleviating motor symptoms and reducing dopaminergic med-
ication. Tabbal et al. used a force transducer to measure rigidity across the elbow, and
gyroscope to measure the angular velocity of hand rotation in 52 PD subjects [128]. The
participants were tested under 4 DBS conditions: both on, left on, right on and both off.
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They quantified the rigidity, bradykinesia and gait speed of the participants. The results
showed there was a significant improvement in kinematic inhibitions due to DBS. Also,
PD patients with DBS ‘OFF’ status have larger Lempel-Ziv Complexity (LZC) value com-
pared to when they are in DBS ‘ON’ state [42]. Wearable sensors were also used to evaluate
the efficacy of nocturnal apomorphine infusion in patients suffering from nocturnal hypoki-
nesia [17].
In Figure 4.3, we can observe the trend of research in assessing the efficacy of PD
treatment. The interest in this area has grown at a slow rate in the last 10 years and from
Figure 4.11 and Figure 4.14, it is observable that wearable and biopotential devices are
commonly used devices in this field. The classification criteria for the papers included in
this category are described in Table 4.1.
Figure 4.3: Articles published in last 10 years focusing on Predicting Response to Treatment.
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2. Therapy/Rehabilitation: Developing an efficient rehabilitation plan for a PD patient
is very important. Rehabilitation techniques may use assistive cues to help the patients
in their daily activities or to improve the activity itself. In the last 10 years, a significant
number of research (140) has been done on assisting the rehabilitation techniques. A lot of
work has also concentrated on coming up with methods to alleviate motor symptoms like
freezing of gait (FoG) and tremor but using auditory, haptic or vibratory cues. The decline
in motor and cognitive functionalities in PD patients lead to increased risk of falling and
reduced quality of life. In-home music-contingent stepping-in-place (SIP) training pro-
gram use wearable sensor-based technology platforms to improve step automaticity during
Dual-Task. Chomiak et al. conducted a study to test the feasibility and efficacy of such a
platform. 4-week research using the sensor system embedded in an iPod Touch was used
to calculate step height [30]. The measurements were further used to trigger auditory feed-
back in real-time through wireless headphones. The study showed that wearable systems
could be used effectively for music-contingent SIP training.
Sensory cueing is one of the most common methods used for facilitating stepping in
people with PD. Recorded sounds of action relevant tasks are more effective in reducing
gait variability in PD patients without freezing of gait (nFoG). In their work, Young et al.
studied the efficacy of such auditory cues in PD patients with FoG [144]. They used 4
different auditory cues and asked 19 PD patients (10 nFoG and 9 FoG) to perform a SIP
task with each of the prompts. The results showed that with action-specific tasks there
was a significant reduction in variation and the potential of using action-specific sensory
cues for Parkinson’s patients with freezing of gait. Another mobile monitoring system for
detection and unfreezing of gait (deFOG) uses a wearable inertial sensor for recognizing
FoG episodes with minimum latency and deliver acoustic cues using a wearable headset to
unfreeze the gait [67]. Moore et al. recorded the vertical linear acceleration of the left shank
using an ankle-mounted sensory array [90]. They defined Freeze Index (FI) as the ratio
34
between the freeze-band and the locomotor-band of the power analysis of the accelerometer
measurements. An FI higher than a chosen threshold was classified as “freeze”. Such a
mobile monitoring system can provide useful feedback and improve management of FoG in
PD. Hand tremor is the most common PD symptom. It prevents patients from performing
daily activities, i.e., eating, writing, etc. Vidya et al. in their study have used a coin-
type vibration motor on the patients’ wrist and a micro-controller for generating random
vibration patterns by using Pulse Width Modulation [136]. The induced vibration on the
wrist distracts the patient’s brain from the biomechanical feedback loop with the hand and
reduces the hand tremor.
Spatial-temporal parameters of gait were evaluated by Jenkins et al. using an instru-
mented carpet, and muscle activation were recorded using surface EMG [65]. Forty sub-
jects were tested while using a facilitatory (ribbed) insole and a conventional (flat) insole
while walking 20 feet. The results of the experiments showed that using facilitatory insole
improved the single-limb support time significantly. Moreover, the use of facilitatory insole
normalized the muscle activation sequence of the tibialis anterior. These changes can lead
to an overall improvement in the gait quality and stability of the patients. Ginis et al. used a
Figure 4.4: Articles published in last 10 years Focusing on Therapy or Rehabilitation of Patients.
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motion-capturing system in a 3D camera-based gait laboratory to investigate differences in
toe-clearance between people with PD and age-matched healthy elderly [51]. The partici-
pants walked for 2 minutes at comfortable pace under 3 conditions: (i) single-task walking,
(ii) attending to heel strike during single-task walking, and (iii) dual-task walking. Results
showed the people with PD had maximal toe clearance and the attention strategy to focus
on heel strike improved the stride length when compared to dual-task walking.
The focus of researchers on improving rehabilitation strategies for people suffering
from PD have risen steadily in the last 10 years as shown in Figure 4.5. Table 4.2 describes
the classifying approach of papers related to Therapy/Rehabilitation.
3. Prognosis/Monitoring Disease Progression: The assessment of the condition and
severity of the symptoms of PD patients depends primarily on the clinician’s judgment and
the patient’s feedback. Since these techniques are sub-optimal and are limited by subjec-
tivity and recall bias, objective home-based monitoring is required. Figure 3.2 shows that
between 2008 and 2018, 288 (36%) papers dealt with problems related to tracking of PD
patients, assisted living for patients, evaluating the severity of PD symptoms in a patient
and evaluating the progression of the disease in general. Zwartjes et al. developed an am-
bulatory monitoring system that provides a complete motor assessment of a PD patient by
simultaneously analyzing motor activities and the severity of several symptoms like tremor,
bradykinesia and hypokinesia [149]. The physical movements of 6 PD patients and 7 HCs
were measured using a set of 4 inertial sensors and simultaneously video-recorded. The re-
sults showed high accuracy in assessing tremor, bradykinesia and hypokinesia, and proved
that it could be used to evaluate PD motor symptoms to optimize treatment.
Another study in 2016 suggested the quantification of tremors in Parkinson’s patients
using smartwatches [32]. This Wireless Body Area Network system is composed of wear-
able sensor nodes (Android Wear) and one sink node (Android Smartphone). Twelve PD
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patients were recruited to perform several activities but were only analyzed during rest.
The tremors in the patients were recorded and analyzed in the form of linear acceleration
and angular rotation as a function of time. They concluded that this system could be used
for determining the evolution of Parkinson’s Disease in stage 3 and stage 4 patients. Wan
et al. used a smartphone to estimate the severity of Parkinson’s Disease in a patient [139].
The study used the UCI data set of voice recording and human activity collected using a
smartphone. After extracting features from this data, they ran different classifiers (KNN,
Random Forest, Logistic Regression and DMLP). After analyzing the results, they con-
cluded that DMLP performed better than all the other algorithms and that such an approach
can improve the precision of treatments and intervention. A recent study proposed the
quantification of rest tremors using wearable sensors and a fuzzy inference system [123].
Fifty-seven PD patients underwent a full motor examination on 12 different sessions dur-
ing which the participants wore a sensor unit on each limb. Fuzzy inference system was
applied on the tremor amplitudes measured from the gyroscope data.
In a paper published by Ba¨chlin et al., they developed a wearable assistant to detect
FoG events during ambulatory movements [8]. The wearable system uses on-body accel-
eration sensors to measure patients’ movements by analyzing the frequency component of
each activity to detect FoG events automatically. Ten PD patients were tested while per-
forming several walking tasks. The system achieved a sensitivity of 73.1% and specificity
of 81.6% while detecting FoG. Baye´s et al. conducted experiments to analyze the ability
of the REMPARK System to detect ON-OFF fluctuations [10]. The system is composed of
a sensor and a smartphone. The sensor is worn as a belt near the pelvic region and trans-
mits acceleration data, which are analyzed in real-time by the device microcontroller and
transferred to the smartphone via Bluetooth. The algorithms in the device microcontroller
use the sensor data to analyze gait, dyskinesia and motor states. After testing the device
on 41 patients with moderate to severe idiopathic PD, they concluded that the REMPARK
37
system can accurately evaluate ON-OFF fluctuations in PD patients.
Timed Up and Go test (TUG) is a commonly used clinical test to evaluate balance and
mobility. Salarian et al. proposed an instrumented TUG called iTUG using portable iner-
tial sensors [121]. Twelve patients in early stages of PD were instrumented with inertial
sensors and were asked to perform the TUG test. Their recordings from the inertial sensors
improved the TUG test in several ways: automatic detection and separation of subcompo-
nents, detailed analysis of each one of them and higher sensitivity than TUG. Robichaud
et al. used surface electromyography (sEMG) to evaluate whether changes in EMG pattern
during rapid point-to-point movement can be used to distinguish PD patients from healthy
controls, and also to determine if the EMG pattern can reflect the severity of PD in the
patients [115]. Three groups of 10 PD subjects and 10 HCs performed rapid point-to-point
elbow flexion movements. The observations from the experiments showed that the EMG
patterns show neurophysiological measures that can objectively distinguish between PD
subjects and HCs and also correlate with disease severity.
In another study, Memedi et al. recorded the upper limb movement data of 65 PD
patients and 10 HCs as they performed a spiral drawing task on a digitized touch screen
telemetry device [87]. The study aimed to characterize motor symptoms like bradykinesia
and dyskinesia objectively and to help in automating the visual inspection process of spiral
drawing task. The features extracted from the recorded data were fed to a classifier and an
accuracy of 84% was achieved in classifying the motor symptoms. Lately, researchers have
been focusing on non-motor symptoms like emotions, fatigue, etc. to assess the progression
of PD in a patient. For example, Dietz et al. investigated emotional processing in non-
demented individuals with PD [38]. Seventeen non-demented PD patients and 16 HCs
were shown pleasant, neutral and unpleasant pictures while their electroencephalography
(EEG) data were recorded. Late positive potential (LPP) was measured from the EEG data.
Apathy, anxiety and depression were assessed in all of the subjects using questionnaire. It
38
Figure 4.5: Articles published in last 10 years Focusing on Prognosis or Monitoring of Disease and
Symptom Severity.
was observed that LPP amplitude during unpleasant picture-viewing was most attenuated
for patients reporting high apathy. Other studies like the one conducted by Ricciardi et al.
recorded facial expressions of 40 PD patients investigated the relationship between reduced
facial expressiveness and altered emotion recognition in PD [110].
The plot in Figure 4.5 shows how the interest of research in this area rose in the last
10 years. Specifically, in the past 3 years, the number of papers published in this area has
grown at an exponential rate. Figure 4.11 shows that all modern measuring device has
been used in this area, while Figure 4.14 shows that wearable devices are the most used
device in these applications. The classification strategy for the articles in this category is
illustrated in Table 4.3.
4. Diagnosis: Till date, the diagnosis of PD is dependent on clinical assessment by neu-
rologists using traditional rating scales like UPDRS, MDS-UPDRS or H&Y scale. Expen-
sive imagery equipment like MRI, SPECT and PET are useful to supplement the clinician’s
assessment. These techniques are prone to inter-rater and inter-clinic subjectivity and can
39
lead to an incorrect diagnosis. Since a correct diagnosis is of prime importance, several re-
searchers have invested their time in working on improved strategies for diagnosis, which
are objective and inexpensive. Raethjen et al. investigated the corticomuscular coherence
of Parkinsonian tremor [109] and recorded the scalp EEG data and EMG data from fore-
arm flexors and extensors. This study included tremor data recorded from 21 PD patients
and the results showed different cortical representations and corticomuscular interaction
of the fundamental and first harmonic frequencies of Parkinsonian tremor. Yoneyama et
al. developed an accelerometer-based gait analysis system to differentiate PD patients with
gait disorder from healthy controls [143]. They used a single accelerometer attached to
the waist of the participants while performing ambulatory activities. A total of 10 PD sub-
jects were included in the study along with 17 age-matched healthy controls. The results
of the experiments showed that the average index for PD patients with gait disorder was
statistically smaller in value than healthy subjects. Padma G et al. developed a Fiber Bragg
Grating Tremor Measurement (FBGTM) device based on a cantilever vibration method
to measure hand tremor in PD subjects [131]. The Fiber Brag Grating sensor measured
the strain variations created over the cantilever, due to the hand tremor. The frequency
analysis of the recorded data can indicate the subject being susceptibility to PD. In recent
years, acceleration and EMG measurements were used by Zhang et al. to develop a posture
assessment-based system to differentiate between Parkinson’s Tremor (PT) and Essential
Tremor (ET) [146]. Postural and rest tremor was recorded in 50 subjects, while they under-
went 2 experiment sessions of the experiment. The results indicated that arm-rested posture
can assist in tremor differentiation.
Muscle activity has been identified as an essential biomarker of early diagnosis of
Parkinson’s Disease. Annesse et al. implemented a Qualitative Gait Analysis platform
for the extraction of muscular response features while performing ordinary activities in PD
patients [3]. They proposed a method for quantification of PD symptoms by identifying the
40
real-time modulation of the muscular index by using 8 EMG wireless nodes positioned on
the lower limbs. The platform was examined on 2 PD patients and 2 healthy individuals and
the validity of the proposed solution was verified. Another study by Meigal et al. evaluated
a variety of novel surface electromyography (sEMG) characteristics of the brachii muscle
in patients with PD [86]. Nineteen PD patients, 20 healthy age-matched controls and 20
young controls participated in the clinical experiment where they performed a submaximal
isometric holding test. The analyses suggested that the most significant difference between
the group of subjects was found in the loading condition when no additional weights were
applied in the isometric elbow flexion. They further concluded that sEMG parameters can
differentiate between PD subjects from healthy controls and can be used in assessing the
severity of PD.
With the rise in use of smartphones, home monitoring and diagnostic aid tools have
become possible. Ayena et al. proposed an automatic version of the One-Leg Standing test
(OLS) for assessing the risk of falling among older people, using a smartphone [6]. Seven
healthy elderly, 4 PD subjects and 12 young adults were recruited for the experiments. The
participants completed the OLS test while wearing an instrumented insole to measure the
vertical ground reaction force (vGRF) and the smartphone recorded the data. The subjects’
center of pressure were assessed from the recorded data and was useful for evaluating
the risk of falling. Soubra et al. developed a system using insole sensors to measure the
vGRF to identify abnormal gait patterns to detect patients who are potentially affected with
PD [126].
EMG data recorded from the chin of a sleeping PD patient to compare the rapid eye
movement (REM) sleep chin EMG quantitative features between PD patients with or with-
out REM sleep behavior disorder (RBD) [43]. Twenty-seven PD patients were enrolled in
the study and they underwent a full polysomnographic recording. EEG, EMG, and ECG
data were recorded and the submentalis muscle EMG was analyzed. The results showed
41
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high sensitivity and specificity for the diagnosis of RBD in PD patients. Qualitative analysis
of electroencephalographic features has been applied for differential diagnosis between
patients with probable Alzheimer’s Disease (AD), Parkinson’s Disease Dementia (PDD),
or dementia with Lewy bodies (DLB). Garn et al. developed a classifier for differentiating
people suffering from each of the diseases based on quantitative electroencephalography
(QEEG) [47]. 25 QEEG features in 61 dementia patients were compared and classified
using leave-one-out cross-validation. The classification achieved an accuracy, sensitivity,
and specificity of 100% using only the QEEG features, Granger causality and the ratio of
theta and beta1 band powers. These results indicate that classifiers trained with selected
QEEG features can provide valuable input in distinguishing among AD, DLB or PDD
patients.
Analyzing speech disorders is also a prevalent strategy for diagnosis of Parkinson’s
Disease. Campos-Roca et al. extracted various acoustic features from an acoustic data set
of 40 healthy control and 40 PD patients [25]. He used different regularization techniques
to classify the data and the results achieved very high classification accuracy rates. In an-
other study, Tsanas et al. used 4 parsimonious subsets of 132 dysphonia features computer
from an existing data set of 263 samples from 43 subjects [130]. Their goal was to test
the validity of novel algorithms to detect PD. They found that the classification with the
new dysphonia features was able to reach almost 99% accuracy. More non-invasive strate-
gies for detecting PD have been developed recently. For example, Ghosh et al. developed
an analysis system to obtain EEG features from the temporal lobe representing the work-
ing memory output during the memory encoding process of unknown people’s face [50].
Kotsavasiloglou et al. applied a machine-learning classification approach to analyze the
line-drawing performance of 24 PD patients and 20 HCs [70]. Their results showed this
technique could achieve accuracy of 91% in differentiating between PD patients and HCs.
Figure 4.6 shows that the interest of research in this area has always been high and
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Figure 4.6: Articles published in last 10 years Focusing on Diagnosis of Parkinson’s Disease.
also grew at a constant rate. Furthermore, Figure 4.11 shows that every significant device
has been used in this area and audio recording devices have almost entirely been used for
diagnostic purposes. Also, Figure 4.14 shows that wearable and biopotential devices are
the most used device in these applications. Table 4.4 list the articles in this category and
describes the classification strategy.
The development in new and portable devices along with improved algorithms have
opened up new techniques of assessment of Parkinson’s Disease. Advanced methods have
enabled more convenient data collection for remote monitoring and tools for diagnostic aid.
In the last 3 years, the number of papers that deal with the supervision of patients’ symp-
toms and the severity of their symptoms has grown significantly. From Figure 4.7(a-d),
we can observe that after 2015 the number of papers published that focus on Prognosis/-
Monitoring of Parkinson’s Disease Progression and Severity of Symptoms have increased
at a much higher rate while the growth in the number of papers focused on other applica-
tion areas have stayed at a near-constant rate. New and upcoming wearable devices have
also enabled advanced rehabilitation techniques, and a lot of focus has gone in developing
modern rehabilitation or symptom suppression techniques. Figure 4.7(a) shows the trend
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Figure 4.7: Articles published in last 10 years by PD application area. (a) Publications that are
focusing on Predicting Response to Treatment, (b) Publications that are focusing on improving
Therapy and Rehabilitation techniques, (c) Publications that are focusing on contributing to im-
proving Diagnosis of PD, (d) Publications that are focusing on Prognosis and Monitoring of PD, its
symptoms and assessing severity
in the number of papers that focus on validating the efficacy of a treatment plan.
It is crucial to evaluate the response of a patient to the prescribed treatment as it enables
the clinician to change the dosage of medication or change the medicine altogether. But, the
number of papers that focus on measuring the efficacy of a treatment plan for Parkinson’s
Disease using modern technologies has not grown significantly.
4.2 Measured Symptoms Included in This Study
After reviewing 778 papers, we were able to identify the major symptoms that scien-
tific studies focus on while developing a solution for PD assessment. The symptoms are
broadly classified as “Motor”, “Non-motor” or “Mixed” and are listed in Table 3.2. The
motor symptoms are primarily visible in a patient; thus a majority of exploration in the last
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decade has been in assessing these motor symptoms like Gait disturbance, Tremor, Motor
activity, Freezing of Gait, etc. Inertial data collected from IMUs used in wearable devices
are widely used in monitoring gait parameters, recording tremor, motor activities, detect-
ing FoG events, assessing bradykinesia and dyskinesia (ON/OFF Stages), etc. Force and
pressure sensors placed under the shoe or in an insole sensor are used for measuring the
ground reaction force, which is a popular parameter for analyzing gait. EMG sensors are
used for monitoring the muscular response of a person. More sophisticated instruments
like digitized tablets and smart pens are used to analyze the hand movement and pressure
while writing.
Figure 3.4 shows the number of publications measuring the different motor and non-
motor symptoms. Gait disturbances are prevalent in PD patients, and most studies have
focused on measuring gait symptoms. It is followed by tremor and FoG which are also
common symptoms of PD. Many studies have also measured movement disorders like
bradykinesia and dyskinesia with the help of modern technologies. Several non-motor
disabilities of PD are measure by studying the nerve/brain signals, cognitive activity, hand-
writing, emotion, etc. In the last 10 years, researchers have mostly focused on gait pa-
rameters and tremor for PD assessment. Figure 4.8 shows the trend in which the focus on
gait and tremor has progressed in the last decade. It can be observed that following 2012
more research studies have focused on gait than tremor, even though the number of papers
for each of these symptoms kept growing. With the popularity of wearables and with the
development of advanced IMUs measuring of gait parameters became easier.
4.3 Most Commonly Used Devices
We investigated the 778 articles published between January 1, 2008, and December 31,
2018, and identified the major types of devices that are used in scientific research in the
assessment of Parkinson’s Disease and its symptoms. The primary categories as described
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before are “Wearable Devices”, “Biopotential Devices”, “Cueing Devices”, “Motion Cap-
turing Devices”, “Audio Recording”, “Video Recording”, “Force/Pressure” and “Smart-
phone”. Devices that did not fall under these categories were marked as “Other”. The
criteria for a device to be classified under these categories are elaborated in Section 3.3.3.
Of the papers reviewed, 41% used a Wearable device for collecting the data, 20% papers
used Biopotential devices, 7% used Audio Recording devices, 6% used Motion Capturing
systems, 6% used different Cueing devices like auditory, haptic or visual cues. Other pa-
pers also used Video Recording devices, Smartphone, etc. Figures 3.5 and 4.9, show that
the Wearable devices and Biopotential devices are the most used devices in the studies re-
lated to Parkinson’s assessment. The growth in the number of papers using Wearables or
Biopotentials is shown in Figure 4.10(a-b). Biopotential devices like Electroencephalo-
gram (EEG), Electrocardiogram (ECG), Electromyogram (EMG) and Electrooculogram
(EOG) have been popular in assessing the stage of a patient who has Parkinson’s Disease.
Figure 4.8: Articles published in last ten years measuring Gait or Tremor using modern technology
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EEG recordings are prevalent in measuring the neural activity of a patient and is a very
popular biomarker of Parkinson’s Disease [109, 98, 44, 28]. EEG data is also useful for
assessing other non-motor symptoms like sleep topics, dementia, cognitive activity and
mixed symptoms like saccades [21, 81, 31, 132, 54, 64]. Similarly, muscular activities are
also instrumental in detecting and assessing Parkinson’s, and EMG recordings are benefi-
cial in analyzing the muscle activity of a person [24, 108, 39, 4, 82]. ECG and EOG are
also used by many researchers to study the heart rate and optical movements, respectively,
to assess PD in patients [69, 1, 75]. Figure 4.10(a) suggests that the number of papers
that use biopotential devices to evaluate PD symptoms has grown at a constant rate. With
the development of portable Biopotential devices and the fact that many Wearable devices
now also have Biopotential sensors like EMG and EEG, more scientists are expected to use
wearable devices for PD assessment in the future.
Due to the growth in the overall interest in the assessment of Parkinson’s Disease (Fig-
ure 4.2), the number of studies about the device has grown in the last decade as shown in
the heat-map in Figure 4.9. In the last decade, particularly in the past 5 years, they have
Figure 4.9: Distribution of articles published between 2008-2018 related to the assessment of
Parkinson’s Disease using modern technology
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focused on the assessment of Parkinson’s Disease with modern technologies have grown
significantly. Devices like Motion Capturing systems, Audio Recording, Smartphone are
being used more in the last several years and are expected to be used more in the coming
future for home monitoring applications. The use of Wearable and Biopotential devices has
been steadily growing in the last 10 years.
In Section 3.3.3, we have elaborated on the different devices we categorize as “Wear-
able”. Mostly, any wireless device that can be placed on any part of a subject’s body to
collect some relevant data can be called a wearable device. Such devices usually have one
or multiple sensors embedded in them for collecting the data, and then the raw data is either
transmitted via some communication interface, i.e., Bluetooth or Zigbee, to a processing
unit or is processed on a microcontroller in the device itself. Different types of sensors
like accelerometer, gyroscope, magnetometer, temperature, force, pressure, etc. have been
used individually or together in the research of Parkinson’s assessment [57, 58, 5, 66, 140,
80, 92, 125, 88]. Wearable devices have also been developed to incorporate Biopotential
Figure 4.10: (a) The papers published between 2008 and 2018 that use Biopotential devices for PD
assessment. (b) The papers published between 2008 and 2018 that use Wearable devices for PD
assessment. The solid line shows the trend of the publications in the last 10 years
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sensors like EMG which are used to record muscle activity data [62, 113, 146, 119, 20, 71].
Other sensors like insole force or pressure sensors have been used to evaluate the vertical
ground reaction force generated when the subject is walking to assess their gait, balance or
posture [147, 85, 63, 73, 97, 34, 7]. Figure 4.10(b) shows that the number of papers pub-
lished using wearable devices has grown at an exponential rate in the last 10 years and is
expected to keep growing. Wearable devices have been useful in all four application areas
as shown in Figure 4.11.
Cueing devices have been used extensively for Therapeutic and Rehabilitation pur-
poses. Active cueing such as vibration and auditory feedback have also been used for
suppression of symptoms like FoG and tremor. Visual cues have been used by differ-
ent scientific studies to develop strategies for assisting walk of PD patients [99, 9, 22].
Wireless headphones have been used to give auditory feedback to patients for improved
motor activity, gait training, and balance training [9, 27, 33, 112]. Moreover, auditory
and vibratory cues have been used to help a patient break out of a freeze or suppress their
Figure 4.11: Percentage of publications between 2008-2018 using different novel technologies for
PD assessment by application areas
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tremor [67, 8, 77, 106, 136, 84, 26, 46]. From Figure 4.11, we can observe that around
90% of the work using cueing systems are focused on improving the therapeutic strategies
and rehabilitation plans.
Audio recording devices like microphones are used to record the speech while a subject
talks or perform a specific vocal task. The recorded voice sample is then analyzed to
identify features that can denote the presence of Parkinson’s Disease or even evaluate the
severity of the disease. Figure 4.11 shows that audio recording devices are mostly used for
Diagnosis or Diagnosis Aid (80%) [145, 124, 11, 148, 2, 89].
4.4 Discussion
The heat-map in Figure 4.12 shows the number of times a specific motor symptom as-
sessed to develop a solution to a particular application area. Gait abnormality is the most
popular motor symptom in PD assessment and also across all of the application areas apart
from “Predicting Response to Treatment”. The motor symptoms that are most commonly
monitored among applications focusing on “Predicting Response to Treatment” are assess-
ing bradykinesia and dyskinesia. They primarily monitor the ON/OFF stages and evaluate
Figure 4.12: Thermal map indicating the number the publications between 2008-2018 that measure
the motor symptoms of PD application areas. The darker the color, the higher the number.
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Figure 4.13: Thermal map indicating the number the publications between 2008-2018 that measure
the non-motor symptoms of PD application areas. The darker the color, the higher the number.
the muscle activities. Tremor and Freezing of Gait are common motor symptoms in a PD
patient and are also used as biomarkers for objective assessment of PD. Analyzing the
balance and posture of a patient is a common strategy used in prognosis and therapy.
Many scientific researchers are now focusing on non-motor symptoms such as cogni-
tive impairment, dementia, and depression. These can be more disabling for a patient and
therefore, objective assessment is required. Analyzing neural response measurements is a
common strategy used by clinicians and researchers for better diagnosis, monitoring and
analyzing the response to treatment as shown in Figure 4.13. Analyzing the cognitive ac-
tivity of patients is also a strategy used in different application areas. However, it is evident
from the heat-map that the amount of work focusing on severe and disabling symptoms
such as dementia, depression, fatigue, etc. is negligible compared to the motor symptoms.
Figure 4.14 shows the most used devices in different application areas. Wearable de-
vices are the most used device in every category, except in ”Predicting Response to Treat-
ment” where Biopotential devices are favored. Cueing devices are almost as popular as
wearables in applications related to “Therapy and Rehabilitation”, also it is worth noting
that a lot of Cueing devices like headphones can be placed on different parts of a patient’s
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Figure 4.14: Distribution of publications between 2008-2018 related to PD assessment using mod-
ern devices, broken down by application area
body like a Wearable. Audio-recording devices are prevalent in aiding “Diagnosis” but
have not been used in “Predicting Response to Treatment”. Similarly, smartphones have
grown in popularity in the last 5 years (Figure 4.9) but are yet to be used in applications
focused on “Predicting Response to Treatment”. Overall, we can observe that modern tech-
nologies are being used in all 4 areas apart from “Predicting Response to Treatment”, where
the total number of papers published in the last decade itself has been limited (Figure 4.7).
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Chapter 5
CONCLUSIONS AND FUTURE WORK
In this review, we provided a comprehensive overview of the technological solutions
currently implemented for objective assessment of Parkinson’s Disease and the essential
PD features. We have manually reviewed 778 articles from the last decade to identify 4
application areas, eight 8 device categories and the symptoms that are measured. This re-
view also provided an idea of what modern technologies can afford soon. The survey can
help in creating a foundation for developing future studies in this area and also for com-
paring their performance with similar work. This review can provide a platform to stay
updated with the recent work in the field and for the scientists to compare their work with
the latest development in their area. The analysis in return will educate the scientist about
the performance of the novel techniques, essential features to measure, and the appropriate
algorithms. Objective techniques using the necessary technologies, accompanied by the
right algorithms, can aid the diagnosis and management of PD and improve the QoL of
the patients. It can also bridge the gap between the technology professionals and clinicians
and can assist in creating a cohort among all the contributors. From this exploratory re-
view, we were able to judge the trend in which the studies in this field are moving. We
conclude that in the scientific community, the emerging idea is to use unobtrusive systems
for monitoring the progression of a disease from its nascent stage. One of the limitations of
these studies are the limitations of available data sets. The small sample size of subjects a
solution is tested on reduces the generalizability of the solution and also hampers its credi-
bility. Another limitation is the optimal number and the placement of sensors. Furthermore,
there are arguments among the researchers on the correct features that should be extracted
from the sensor signals [117]. Lastly, for automatic assessment of the symptoms, efficient
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algorithms are required to classify the symptoms with high accuracy.
Future work:
• We need to develop a tool to update our repository and to make the entire literature
classification process more streamlined. Currently, we were only able to automate
the filtering and identification of the papers using a Python script, while the fetching
of the documents was done manually from the websites of the 4 sources mentioned
in this review. In the future, we plan on using a tool that can automate this process
and update our repository.
• We plan to include more databases like the Web of Science, Scopus, and Pubmed to
expand our repository with other techniques and solutions used in the assessment of
PD.
• A text segmentation or natural language processing-based classifier for automatic
classification of the papers can increase the number of documents in our repository
and include a broader range of work. It will remove the need for manual inspection
of articles as shown in Figure 3.2.
• An automated classification algorithm will also enable us to inspect entire articles,
not just the Title, Abstract, and Keywords. That will improve the credibility of our
repository and also increase the number of documents.
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